Receptor News and Research

RSS

A magic bullet for superbugs

Attaching an antimicrobial drug, which is activated by light, to a peptide that binds to bacteria and stops them making toxins, produced a "magic bullet" that was highly effective at killing the superbug, methicillin-resistant Staphylococcus aureus (MRSA).

1 Apr 2009

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

Researchers at Georgetown University Medical Center (GUMC) have been able to speed recovery and substantially reduce damage resulting from spinal cord injury in preclinical studies.

1 Apr 2009

Quantum Immunologics announces the filing of two important provisional patent applications

Quantum Immunologics, Inc. (QI), a Florida-based company specializing in cancer immunotherapy, has recently filed two provisional patent applications relating to their work in cancer immunotherapy.

31 Mar 2009

New smoking cessation drug varenicline tartrate shows promise in trials

Research has shown that varenicline tartrate - a novel new drug specifically developed for smoking cessation - allows smokers to abstain from cigarettes significantly longer and more effectively than smokers using a placebo.

31 Mar 2009

Study answers question of timing in use of eptifibatide

An international study to resolve a decade of debate over the best timing for administering an anti-clotting drug for certain heart patients has come up with an answer: It doesn't matter.

30 Mar 2009

New radiation-free targeted therapy detects and eliminates breast cancer tumors in mice

Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.

30 Mar 2009

New cancer genomics web-based tools provide researchers a powerful new to visualize and analyze data

A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.

30 Mar 2009

Targeted drug therapy prevents exercise-induced arrhythmias

A 12-year-old Dutch boy - bedridden for three years because of an inherited cardiac arrhythmia syndrome - can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.

30 Mar 2009

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

Eli Lilly and Company has announced inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia.

29 Mar 2009

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

ARCA biopharma, Inc. has announced that data from the pivotal Phase 3 BEST trial of Gencaro (bucindolol hydrochloride) in patients with advanced chronic heart failure (CHF) was presented at the American College of Cardiology 58 th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida.

29 Mar 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

Researchers reveal mechanism that regulates cancer-causing gene

Two University of Rhode Island scientists have revealed how a cancer causing protein is regulated by reactive oxygen species (ROS) -- a type of stress signal.

29 Mar 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

FABLYN approved in Europe as osteoporosis treatment

Ligand Pharmaceuticals Incorporated has announced that its partner, Pfizer, Inc. has received approval from the European Commission (EC) for FABLYN (lasofoxifene) Tablets, a selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture.

24 Mar 2009

Time (and PPAR-beta/delta) heals all wounds

Mammalian skin requires constant maintenance, but how do skin cells know when to proliferate and at what rate?

23 Mar 2009

p11 protein may lead to faster acting antidepressants

Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

23 Mar 2009